Drugs that contain Vandetanib

1. Caprelsa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7173038 GENZYME CORP Quinazoline derivatives as VEGF inhibitors
Aug, 2021

(2 years ago)

USRE42353 GENZYME CORP Quinazoline derivatives and pharmaceutical compositions containing them
Jun, 2022

(1 year, 9 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8642608 GENZYME CORP Quinazoline derivatives as VEGF inhibitors
Feb, 2022

(2 years ago)

US8067427 GENZYME CORP Pharmaceutical compositions comprising ZD6474
Aug, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-9) Apr 06, 2018
Orphan Drug Exclusivity(ODE) Apr 06, 2018
New Chemical Entity Exclusivity(NCE) Apr 06, 2016

NCE-1 date: 07 April, 2015

Market Authorisation Date: 06 April, 2011

Treatment: For use in patients having symptomatic or progressive medullary thyroid cancer, with unresectable locally advanced or metastatic disease


More Information on Dosage

CAPRELSA family patents

Family Patents